Survival following resection of clinically occult N2 non small cell lung cancer

R. Dalton, S. Keller

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background. The role of resection in Stage IIIA (N2) non-small cell lung cancer (NSCLC) remains controversial despite reported survival rates of 25-40%. This study was undertaken to identify factors associated with a high risk of treatment failure after resection of clinically occult Stage IIIA (N2) NSCLC. Such prognostic factors may identify high risk patients as candidates for future clinical trials of multimodality lung cancer treatment and be important stratification factors in such trials. Methods. The clinical and pathological records of 32 patients with clinical NO pathologic N2 NSCLC who underwent lobectomy (n = 17), pneumonectomy (n = 12), or bilobectomy (n = 3) and complete mediastinal lymph node dissection at Fox Chase Cancer Center from 1987 to 1991 were reviewed. A multivariate analysis of clinical and pathologic variables was performed. Results. Median follow-up was 15 months (range 5-55). Fifty-nine percent have recurred and 44% have died. Median disease free and overall survival were 16 and 19 months, respectively. Two year disease free and overall survival were 24% and 43%, respectively. No patient with more than one level of mediastinal lymph node metastases survived two years free of disease. Univariate and multivariate analysis revealed a longer disease free survival for those receiving adjuvant radiation therapy (19 vs 5 months) but no increase in overall survival. Conclusions. This experience with clinically occult Stage IIIA (N2) NSCLC suggests that multiple levels of mediastinal lymph node metastases predict treatment failure in patients following resection and that adjuvant mediastinal radiation improves disease free but not overall survival.

Original languageEnglish (US)
Pages (from-to)13-17
Number of pages5
JournalJournal of Cardiovascular Surgery
Volume35
Issue numberSUPPL. 1-6
StatePublished - 1994
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Disease-Free Survival
Survival
Treatment Failure
Multivariate Analysis
Lymph Nodes
Neoplasm Metastasis
Pneumonectomy
Lymph Node Excision
Lung Neoplasms
Radiotherapy
Survival Rate
Clinical Trials
Radiation
Neoplasms
Therapeutics

Keywords

  • Carcinoma, non-small cell lung
  • Survival

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Survival following resection of clinically occult N2 non small cell lung cancer. / Dalton, R.; Keller, S.

In: Journal of Cardiovascular Surgery, Vol. 35, No. SUPPL. 1-6, 1994, p. 13-17.

Research output: Contribution to journalArticle

Dalton, R. ; Keller, S. / Survival following resection of clinically occult N2 non small cell lung cancer. In: Journal of Cardiovascular Surgery. 1994 ; Vol. 35, No. SUPPL. 1-6. pp. 13-17.
@article{d403cd4af99743f58b1c516988f80fcc,
title = "Survival following resection of clinically occult N2 non small cell lung cancer",
abstract = "Background. The role of resection in Stage IIIA (N2) non-small cell lung cancer (NSCLC) remains controversial despite reported survival rates of 25-40{\%}. This study was undertaken to identify factors associated with a high risk of treatment failure after resection of clinically occult Stage IIIA (N2) NSCLC. Such prognostic factors may identify high risk patients as candidates for future clinical trials of multimodality lung cancer treatment and be important stratification factors in such trials. Methods. The clinical and pathological records of 32 patients with clinical NO pathologic N2 NSCLC who underwent lobectomy (n = 17), pneumonectomy (n = 12), or bilobectomy (n = 3) and complete mediastinal lymph node dissection at Fox Chase Cancer Center from 1987 to 1991 were reviewed. A multivariate analysis of clinical and pathologic variables was performed. Results. Median follow-up was 15 months (range 5-55). Fifty-nine percent have recurred and 44{\%} have died. Median disease free and overall survival were 16 and 19 months, respectively. Two year disease free and overall survival were 24{\%} and 43{\%}, respectively. No patient with more than one level of mediastinal lymph node metastases survived two years free of disease. Univariate and multivariate analysis revealed a longer disease free survival for those receiving adjuvant radiation therapy (19 vs 5 months) but no increase in overall survival. Conclusions. This experience with clinically occult Stage IIIA (N2) NSCLC suggests that multiple levels of mediastinal lymph node metastases predict treatment failure in patients following resection and that adjuvant mediastinal radiation improves disease free but not overall survival.",
keywords = "Carcinoma, non-small cell lung, Survival",
author = "R. Dalton and S. Keller",
year = "1994",
language = "English (US)",
volume = "35",
pages = "13--17",
journal = "Journal of Cardiovascular Surgery",
issn = "0021-9509",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "SUPPL. 1-6",

}

TY - JOUR

T1 - Survival following resection of clinically occult N2 non small cell lung cancer

AU - Dalton, R.

AU - Keller, S.

PY - 1994

Y1 - 1994

N2 - Background. The role of resection in Stage IIIA (N2) non-small cell lung cancer (NSCLC) remains controversial despite reported survival rates of 25-40%. This study was undertaken to identify factors associated with a high risk of treatment failure after resection of clinically occult Stage IIIA (N2) NSCLC. Such prognostic factors may identify high risk patients as candidates for future clinical trials of multimodality lung cancer treatment and be important stratification factors in such trials. Methods. The clinical and pathological records of 32 patients with clinical NO pathologic N2 NSCLC who underwent lobectomy (n = 17), pneumonectomy (n = 12), or bilobectomy (n = 3) and complete mediastinal lymph node dissection at Fox Chase Cancer Center from 1987 to 1991 were reviewed. A multivariate analysis of clinical and pathologic variables was performed. Results. Median follow-up was 15 months (range 5-55). Fifty-nine percent have recurred and 44% have died. Median disease free and overall survival were 16 and 19 months, respectively. Two year disease free and overall survival were 24% and 43%, respectively. No patient with more than one level of mediastinal lymph node metastases survived two years free of disease. Univariate and multivariate analysis revealed a longer disease free survival for those receiving adjuvant radiation therapy (19 vs 5 months) but no increase in overall survival. Conclusions. This experience with clinically occult Stage IIIA (N2) NSCLC suggests that multiple levels of mediastinal lymph node metastases predict treatment failure in patients following resection and that adjuvant mediastinal radiation improves disease free but not overall survival.

AB - Background. The role of resection in Stage IIIA (N2) non-small cell lung cancer (NSCLC) remains controversial despite reported survival rates of 25-40%. This study was undertaken to identify factors associated with a high risk of treatment failure after resection of clinically occult Stage IIIA (N2) NSCLC. Such prognostic factors may identify high risk patients as candidates for future clinical trials of multimodality lung cancer treatment and be important stratification factors in such trials. Methods. The clinical and pathological records of 32 patients with clinical NO pathologic N2 NSCLC who underwent lobectomy (n = 17), pneumonectomy (n = 12), or bilobectomy (n = 3) and complete mediastinal lymph node dissection at Fox Chase Cancer Center from 1987 to 1991 were reviewed. A multivariate analysis of clinical and pathologic variables was performed. Results. Median follow-up was 15 months (range 5-55). Fifty-nine percent have recurred and 44% have died. Median disease free and overall survival were 16 and 19 months, respectively. Two year disease free and overall survival were 24% and 43%, respectively. No patient with more than one level of mediastinal lymph node metastases survived two years free of disease. Univariate and multivariate analysis revealed a longer disease free survival for those receiving adjuvant radiation therapy (19 vs 5 months) but no increase in overall survival. Conclusions. This experience with clinically occult Stage IIIA (N2) NSCLC suggests that multiple levels of mediastinal lymph node metastases predict treatment failure in patients following resection and that adjuvant mediastinal radiation improves disease free but not overall survival.

KW - Carcinoma, non-small cell lung

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0028672611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028672611&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 13

EP - 17

JO - Journal of Cardiovascular Surgery

JF - Journal of Cardiovascular Surgery

SN - 0021-9509

IS - SUPPL. 1-6

ER -